Form 4: Tenaya Therapeutics 10% Owner Sells Shares

A 10% owner and director of Tenaya Therapeutics, The Column Group, reported significant sales of common stock totaling over 4.3 million shares across two days in February 2026.

Summary

• The Column Group III GP, LP, a 10% owner and director of Tenaya Therapeutics, Inc. (TNYA), reported multiple sales of common stock.
• On February 10, 2026, 161,422 shares were sold at a weighted average price of $0.8161, and 182,295 shares were sold at the same price.
• On February 11, 2026, 1,905,115 shares were sold at a weighted average price of $0.6808, and 2,151,458 shares were sold at the same price.
• These transactions were executed pursuant to a Rule 10b5-1 trading plan.
• Following these transactions, The Column Group III, LP indirectly holds 2,348,183 shares, and The Column Group III-A, LP indirectly holds 2,651,817 shares.
• TCG Opportunity III LP indirectly holds 49,313,559 shares, though no transactions were reported for this specific holding in this filing.
• Peter Svennilson and Tim Kutzkey have been added as Reporting Persons due to the retirement of a managing partner of TCG III GP LP and a managing member of TCG Opportunity GP LLC.

Sentiment

Score: 3

Explanation: StockSavvy.ai views this as a moderately negative signal due to the substantial volume of shares sold by a significant insider and director, coupled with the declining sale prices, despite the transactions being pre-planned under a Rule 10b5-1 plan.

Positives

• The sales were conducted under a Rule 10b5-1 plan, indicating pre-scheduled transactions rather than a reaction to immediate negative news.

Negatives

• Significant insider selling by a 10% owner and director could be perceived negatively by the market, especially given the large volume of shares sold (over 4.3 million shares).
• The sales occurred at declining prices, from a weighted average of $0.8161 on February 10, 2026, to $0.6808 on February 11, 2026.

Risks

• Large insider sales by a significant shareholder and director may signal a lack of confidence in the company's future prospects or valuation, potentially leading to negative market sentiment.
• The declining sale prices suggest a downward trend in the stock's value around the transaction dates.

Future Outlook

The filing does not contain any explicit forward-looking statements or guidance regarding the company's future performance or strategic direction.

Management Comments

• The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range.

Industry Context

StockSavvy.ai notes that insider selling, even when pre-planned via a 10b5-1 plan, can sometimes be interpreted by the market as a signal, particularly in the biotechnology sector where investor confidence is often tied to long-term growth prospects and insider alignment. The declining share price during the sale period could reflect broader market sentiment or specific company-related developments for Tenaya Therapeutics, a company focused on gene therapies for heart disease.

Comparison to Industry Standards

• Insider selling is a common occurrence across all industries, but the scale and timing can be significant. For a biotech company like Tenaya Therapeutics, which is often pre-revenue or early-revenue, large insider sales can be scrutinized more heavily than in mature, stable industries.
• While the sales were under a 10b5-1 plan, which is a standard practice to avoid accusations of trading on material non-public information, the volume of shares sold by a 10% owner and director is notable.
• Compared to other biotech firms where founders or early investors often hold significant stakes, the reduction in holdings by a major institutional investor like The Column Group could be seen as a strategic portfolio adjustment or a response to specific valuation assessments.

Management Changes

Related Party Transactions

• Sales of common stock by The Column Group entities, which are 10% owners and have director representation on Tenaya Therapeutics' board, constitute related party transactions.

Stakeholder Impact

• Shareholders: May interpret the significant insider selling as a negative signal, potentially leading to decreased investor confidence and downward pressure on the stock price.
• Management: The change in reporting persons (addition of Peter Svennilson and Tim Kutzkey) reflects an internal restructuring within The Column Group, which indirectly impacts the beneficial ownership structure.

Next Steps

• The reporting person undertakes to provide full information regarding the number of shares sold at each separate price within the reported ranges upon request.

Key Dates

Recommendation

The substantial volume of shares sold by a 10% owner and director, totaling over 4.3 million shares, combined with the declining average sale prices from $0.8161 to $0.6808 over two days, indicates a significant lack of confidence from a major insider. While these sales were executed under a Rule 10b5-1 plan, the sheer scale and the downward price trend suggest a negative outlook for Tenaya Therapeutics' stock in the near to medium term. A seasoned investor would likely view this as a strong signal to reduce or exit positions.

Keywords

Tenaya Therapeutics, TNYA, SEC Form 4, Insider Selling, Beneficial Ownership, The Column Group, Stock Sale, Director Transaction, 10% Owner, Rule 10b5-1